Commentary: Biosimilars are coming, and patients could benefit

03/6/2009 | Genetic Engineering & Biotechnology News

Regulating the development of follow-on biologics as recommended in President Barack Obama's first budget could benefit patients if the law "appropriately balances the need for competition with the need to protect innovation," writes James Bianco, CEO and director of Cell Therapeutics. The law should help bring follow-on biologics to the market quickly but only after their safety and efficacy have been tested in clinical trials, Bianco writes.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL